MX2013005165A - Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico. - Google Patents

Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico.

Info

Publication number
MX2013005165A
MX2013005165A MX2013005165A MX2013005165A MX2013005165A MX 2013005165 A MX2013005165 A MX 2013005165A MX 2013005165 A MX2013005165 A MX 2013005165A MX 2013005165 A MX2013005165 A MX 2013005165A MX 2013005165 A MX2013005165 A MX 2013005165A
Authority
MX
Mexico
Prior art keywords
alkoxyimidazol
carboxylic acid
crystalline forms
biphenyl carboxylic
ylmethyl
Prior art date
Application number
MX2013005165A
Other languages
English (en)
Inventor
Paul R Fatheree
Venkat R Thalladi
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MX2013005165A publication Critical patent/MX2013005165A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas de sal cristalina de ácido 4´-{2-etoxi-4-etil-5-[((S)-2-mer capto-4-metilpentanoilamino)metil]imidazol-1-ilmetil}-3´-fluoro bifenil-2-carboxilico. La presente invención también proporciona composiciones farmacéuticas que comprenden los compuestos cristalinos, procesos e intermediarios para preparar los compuestos cristalinos, y métodos para usar los compuestos cristalinos para tratar enfermedades tales como la hipertensión.
MX2013005165A 2010-11-10 2011-11-09 Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico. MX2013005165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10
PCT/US2011/059895 WO2012064807A1 (en) 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Publications (1)

Publication Number Publication Date
MX2013005165A true MX2013005165A (es) 2013-07-05

Family

ID=45003086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005165A MX2013005165A (es) 2010-11-10 2011-11-09 Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico.

Country Status (19)

Country Link
US (3) US8362060B2 (es)
EP (1) EP2638017B1 (es)
JP (2) JP2013542258A (es)
KR (1) KR20130130730A (es)
CN (1) CN103189362B (es)
AR (1) AR083828A1 (es)
AU (1) AU2011326622B2 (es)
BR (1) BR112013011715A2 (es)
CA (1) CA2812598A1 (es)
CO (1) CO6741224A2 (es)
ES (1) ES2567721T3 (es)
HK (1) HK1187919A1 (es)
IL (1) IL225303A0 (es)
MX (1) MX2013005165A (es)
NZ (1) NZ609804A (es)
RU (1) RU2013126403A (es)
SG (1) SG189448A1 (es)
TW (1) TW201300366A (es)
WO (1) WO2012064807A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TWI545114B (zh) 2009-09-29 2016-08-11 施萬生物製藥研發Ｉｐ有限責任公司 製備聯苯基咪唑化合物之方法
WO2011109579A1 (en) 2010-03-04 2011-09-09 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Also Published As

Publication number Publication date
BR112013011715A2 (pt) 2017-10-31
US20130267573A1 (en) 2013-10-10
CN103189362A (zh) 2013-07-03
JP2013542258A (ja) 2013-11-21
US20150133518A1 (en) 2015-05-14
HK1187919A1 (zh) 2014-04-17
CN103189362B (zh) 2015-03-11
CO6741224A2 (es) 2013-08-30
US8802709B2 (en) 2014-08-12
KR20130130730A (ko) 2013-12-02
AR083828A1 (es) 2013-03-27
ES2567721T3 (es) 2016-04-26
AU2011326622B2 (en) 2014-12-18
RU2013126403A (ru) 2014-12-20
EP2638017A1 (en) 2013-09-18
IL225303A0 (en) 2013-06-27
WO2012064807A1 (en) 2012-05-18
EP2638017B1 (en) 2016-01-27
CA2812598A1 (en) 2012-05-18
JP2016028061A (ja) 2016-02-25
US20120115920A1 (en) 2012-05-10
US9249105B2 (en) 2016-02-02
US8362060B2 (en) 2013-01-29
SG189448A1 (en) 2013-05-31
TW201300366A (zh) 2013-01-01
AU2011326622A1 (en) 2013-04-04
NZ609804A (en) 2015-02-27

Similar Documents

Publication Publication Date Title
IN2014KN00929A (es)
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
NZ730730A (en) Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1
MY165087A (en) Neprilysin inhibitors
IN2014MN02106A (es)
MX354476B (es) Inhibidores de neprilisina.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
MY170935A (en) Neprilysin inhibitors
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
MX2011011776A (es) Nuevos profarmacos de triptolite.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
IN2014CN01216A (es)
MX2012015100A (es) Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
WO2014170842A3 (en) Substituted alkyl carboxylic acid derivatives as gpr agonists
UA103329C2 (ru) Соли соединений-ингибиторов вич
MY150817A (en) Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
IN2013DN02555A (es)
IN2014CN01217A (es)